PeopleBio Inc

PeopleBio Inc has a liquidity position that is relatively strong in terms of asset coverage, with a current ratio of 4.34, indicating that the company holds significantly more current assets than current liabilities. However, the company's operating cash flow is negative at -2.38 billion KRW, and free cash flow is also negative at -3.19 billion KRW, suggesting that the company is not generating sufficient cash from operations to fund its activities. The company's cash and equivalents amount to 534.7 million KRW, which is less than its long-term debt of 1.53 billion KRW, indicating a net cash outflow position.

In terms of profitability, PeopleBio Inc is currently unprofitable, with a net loss of 3.17 billion KRW and an operating loss of 3.26 billion KRW. The company's return on equity is -19.78%, and its return on assets is -13.74%, both of which are significantly below the industry median for medical equipment and biotechnology firms. The company's gross profit margin is 21.7%, which is in line with the industry median, but its operating margin is -439.3%, indicating a severe underperformance in controlling operating expenses.

The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification increases the company's exposure to market-specific risks, particularly in the biotechnology and medical equipment sectors.

Looking ahead, the company's revenue is expected to remain under pressure, with no clear growth trajectory evident from the available data. The company's capital expenditures are relatively low at -68.9 million KRW, suggesting a conservative approach to asset investment. However, the company's negative operating cash flow and free cash flow indicate that it may need to rely on external financing to fund its operations and growth initiatives.

The company's risk profile is characterized by medium liquidity risk and low dilution risk. The key liquidity flag is the negative net cash position after subtracting total debt, which could limit the company's ability to fund operations without external financing. The company's debt-to-equity ratio is 0.1, indicating a relatively low level of leverage, and there is no indication of near-term dilution pressure from recent filings or transcripts.

Recent events, as disclosed in the company's financial filings, include a significant operating loss and a net loss for the period. The company has not issued any new shares in the recent period, and there are no indications of material changes in its business operations or strategic direction. The company's financial performance is closely tied to its ability to commercialize its products and secure research collaborations, which remain the primary drivers of its revenue.

Revenue grew 12.6% year-over-year to 2.85 billion KRW, indicating top-line expansion despite ongoing operational losses.

The company maintains a low debt-to-equity ratio of 0.1, suggesting a conservative capital structure relative to equity.

Long-term debt decreased to 7.76 billion KRW in the latest period, reflecting a reduction in leverage obligations.

The company faces high credit risk, signaling significant concerns regarding its ability to meet financial obligations.

Operating margin of -4.38% places the company in the bottom quartile compared to 335 medical equipment peers.